Dittadi R, Gion M, Pagan V, Brazzale A, Del Maschio O, Bargossi A, Busetto A, Bruscagnin G
Cancer for the Study of Biological Markers of Malignancy, Regional General Hospital, Venice, Italy.
Br J Cancer. 1991 Oct;64(4):741-4. doi: 10.1038/bjc.1991.390.
Epidermal growth factor receptors (EGFr) were measured using a radioligand binding assay, in membrane preparations from 51 human non-small cell lung cancers and in normal tissue of the same patients. The binding characteristics of EGFr were similar in tumour and normal lung membranes (range of dissociation constant of high affinity sites: 0.1-0.6 nM). However, the concentrations in tumours (median, 16.4 fmol mg-1 of protein; range, 1.5-176) were significantly higher than in normal tissues (median, 7.4 fmol mg-1 of protein; range, 1.9-13.4). The receptor levels in normal tissue were normally distributed. It was therefore possible to define a normal/pathologic cut-off level (12.9 fmol mg-1 of protein). In 57% of cases EGFr in cancer was higher than the cut-off. No relationships were found between receptor concentrations and positivity rates of EGFr and histology, stage, lymph node positivity and pT. A trend for a direct relation between receptor positivity and grading was found.
采用放射性配体结合分析法，在51例人非小细胞肺癌的膜制剂以及同一患者的正常组织中检测表皮生长因子受体（EGFr）。EGFr在肿瘤组织和正常肺组织膜中的结合特性相似（高亲和力位点解离常数范围：0.1 - 0.6 nM）。然而，肿瘤组织中的浓度（中位数为16.4 fmol mg⁻¹蛋白质；范围为1.5 - 176）显著高于正常组织（中位数为7.4 fmol mg⁻¹蛋白质；范围为1.9 - 13.4）。正常组织中的受体水平呈正态分布。因此，有可能确定一个正常/病理临界水平（12.9 fmol mg⁻¹蛋白质）。在57%的病例中，癌症中的EGFr高于临界值。未发现受体浓度与EGFr的阳性率以及组织学、分期、淋巴结阳性和pT之间存在相关性。发现受体阳性与分级之间存在直接关系的趋势。
